Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: Comparison of single-bolus tenecteplase and front-loaded alteplase

Thrombosis Research

Volumn 106, Issue 2, 2002, Pages 113-119

  Szabo, Sebastian ^a   Letsch, Ronald ^b   Ehlers, Raila ^b   Walter, Thomas ^b   Kazmaier, Silke ^b   Helber, Uwe ^b   Hoffmeister, Hans Martin ^a  

^a STÄDTISCHES KLINIKUM SOLINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Fibrin specificity; Myocardial infarction; Procoagulatory effects; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTIPLASMIN; ANTITHROMBIN III; BLOOD CLOTTING FACTOR 12; D DIMER; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENT; HEPARIN; KALLIKREIN; PLASMIN; PLASMIN ALPHA 2; PROCOAGULANT; PROTHROMBIN; TENECTEPLASE; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SPECIFICITY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; ANTIPLASMIN; ANTITHROMBIN III; ASPIRIN; BIOLOGICAL MARKERS; ENZYME ACTIVATION; FACTOR XIIA; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HEMOSTASIS; HEPARIN; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLASMIN; PLATELET AGGREGATION INHIBITORS; PROTHROMBIN; RECOMBINANT PROTEINS; SUBSTRATE SPECIFICITY; THROMBIN; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037089059     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00084-1     Document Type: Article

References (37)

1. Van de Werf F., Adgey J. The Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 354:1999;716-722.
2. Gulba D.C., Barthels M., Westhoff-Bleck M., Jost S., Rafflenbeul W., Daniel W.G., Hecker H., Lichtlen P.R. Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy. Circulation. 83:1991;937-944.
3. Ewald G.A., Eisenberg P.R. Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. Circulation. 91:1995;28-36.
4. Hoffmeister H.M., Szabo S., Kastner C., Beyer M.E., Helber U., Kazmaier S., Wendel H.P., Heller W., Seipel L. Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimen with focus on the kallikrein system and plasmin. Circulation. 98:1998;2527-2533.
5. Keyt B.A., Paoni N.F., Refino C.J., Berleau L., Nguyen H., Chow A., Lai J., Pena L., Pater C., Ogez J. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci U S A. 91:1994;3670-3674.
6. Paoni N.F., Keyt B.A., Refino C.J., Chow A.M., Nguyen H.V., Berleau L.T., Badillo J., Pena L.C., Brady K., Wurm F.M. A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR286-299 AAAA). Thromb Haemost. 70:1993;307-312.
7. Benedict C.R., Refino C.J., Keyt C.A., Pakala R., Paoni N.F., Thomas G.R., Bennett W.F. New variant of tissue human plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation. 92:1995;3032-3040.
8. Angleton P., Chandler W.L., Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation. 79:1989;101-106.
9. Huber K., Rose D., Resch I. Circadian fluctuations of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost. 60:1988;372-376.
10. Gulba D.C., Bode C., Runge M.S., Huber K. Thrombolytic agents - an overview. Ann Hematol. 73(Suppl. 1):1996;9-27.
11. Moser M., Nordt T., Peter K., Ruef J., Kohler B., Schmittner M., Smalling R., Kubler W., Bode C. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase. Circulation. 100:1999;1858-1864.
12. Martinez-Sales V., Vila V., Reganon E., Goberna M.A., Ferrando F., Palencia F.A., Aznar J. Elevated thrombotic activity after myocardial infarction: a 2-year follow-up study. Haemostasis. 28:1998;301-306.
13. Gallimore M.J. Plasma-präkallikrein. Hämostaseologie. 7:1987;166-171.
14. Nuijens J.H., Huijbregts C.C., Eerenberg-Belmer A.J., Meijers J.C., Bouma B.N., Hack C.E. Activation of the contact system of coagulation by a monoclonal antibody directed against a neodeterminant in the heavy chain region of human coagulation factor XII (Hageman factor). J Biol Chem. 264:1989;14300-14305.
15. Rojkjaer R., Schmaier A.H. Activation of the kallikrein/kinin system on endothelial cell membranes. Immunopharmacology. 43:1999;109-114.
16. Colman R.W., Schmaier A.H. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive and proinflammatory attribution. Blood. 90:1997;3819-3843.
17. Cochrane C.G., Griffin J.H. Molecular assembly in the contact phase of the Hageman factor system. Am J Med. 67:1979;657-664.
18. Li C., Gurewich V., Liu J.N. Urokinase-type plasminogen activator induced monocyte adhesion is modulated by kininogen, kallikrein, factor XII and plasminogen. Exp Cell Res. 226:1996;239-242.
19. Lenich C., Pannell R., Gurewich V. Assembly and activation of the intrinsic fibrinolytic pathway on the surface of human endothelial cells in culture. Thromb Haemost. 74:1995;698-703.
20. Cerf M., Raidoo D., Fink E., Fritz H., Bhoola K. Plasma kallikrein in human blood vessels. Immunopharmacology. 44:1999;75-80.
21. Proud D., Kaplan A.P. Kinin formation: mechanisms and role in inflammatory disorders. Annu Rev Immunol. 6:1982;49-83.
22. Torstila I. The plasma kinin system in acute myocardial infarction. Acta Med Scand Suppl. 620:1978;1-62.
23. Hoffmeister H.M., Ruf M., Wendel H.P., Heller W., Seipel L. Streptokinase-induced activation of the kallikrein-kinin system and of the contact phase in patients with acute myocardial infarction. J Cardiovasc Pharmacol. 31:1998;722-764.
24. Agostoni A., Gardinali M., Frangi D., Cafaro C., Conciato L., Sponzilli C., Salvioni A., Cugno M., Cicardi M. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. Circulation. 90:1994;2666-2670.
25. Kleniewsky J., Blankenship D.T., Cardin A.D., Donaldson V. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med. 120:1992;129-139.
26. Stangl K., Laule M., Tenckhoff B., Stangl V., Gliech V., Dubel P., Grohmann A., Melzer C., Langel J., Wernecke K.D., Baumann G., Ziemer S. Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction. Am J Cardiol. 81:1998;841-847.
27. Coppola R., Cristilli P., Cugno M., Ariens R.A., Mari D., Mannucci P.M. Measurement of activated factor XII in health and disease. Blood Coagul Fibrinolysis. 7:1996;530-535.
28. Reddigari S.R., Shibayama Y., Brunnee T., Kaplan A.P. Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem. 268:1993;11982-11987.
29. Miller G.J., Esnouf M.P., Burgess A.I., Cooper J.A., Mitchell J.P. Risk of coronary heart disease and activation of factor XII in middle-aged men. Arterioscler Thromb Vasc Biol. 17:1997;2103-2106.
30. Kohler H.P., Carter A.M., Stickland M.H., Grant P.J. Levels of activated FXII in survivors of myocardial infarction - association with circulating risk factors and extent of coronary artery disease. Thromb Haemost. 79:1998;1-18.
31. Cannon C.P., Gibson M.C., McCabe C.H., Adgey A.A., Schweiger M.J., Sequeira R.F., Grollier G., Giugliano R.P., Frey M., Müller H.S., Steingart R.M., Weaver W.D., Van de Werf F., Braunwald E. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation. 98:1998;2805-2814.
32. Cugno M., Cicardi M., Bottasso B., Coppola R., Paonessa R., Mannucci P.M., Agostoni A. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood. 89:1997;3213-3218.
33. Hessel L.W., Kluft C. Advances in clinical fibrinolysis. Clin Haematol. 15:1986;443-463.
34. Vaziri N.D., Kennedy S.C., Kennedy D., Gonzales E. Coagulation, fibrinolytic, and inhibitory proteins in acute myocardial infarction and angina pectoris. Am J Med. 93:1992;651-657.
35. Rennie J.A., Ogston D. Changes in coagulation factors following acute myocardial infarction in man. Haemostasis. 5:1976;258-264.
36. Gidron E., Margalit R., Oliven A., Shalitin Y. Effect of myocardial infarction on components of fibrinolytic system. Br Heart J. 39:1977;19-24.
37. Pislaru S.V., Van de Werf F. TNK-tPA for acute myocardial infarction: the clinical experience. Thromb Haemost. 82:1999;117-120. (Suppl.).